Navigation Links
HeartWare Reports Third Quarter 2012 Results
Date:11/9/2012

FRAMINGHAM, Mass. and SYDNEY, Nov. 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $22.9 million for the third quarter ended September 30, 2012, compared to revenue of $21.3 million for the same period of 2011.  Revenue from international markets increased approximately 40% to $19.2 million in the third quarter of 2012, from $13.7 million in the third quarter of 2011.  U.S. revenue, which is presently derived from clinical trial activities, was $3.7 million in the third quarter of 2012, compared to $7.6 million in the third quarter of 2011, due to the completed enrollment of the Company's Destination Therapy clinical trial in the second quarter of this year.  Currency fluctuations decreased revenue by nine percent in the third quarter compared to the same period in 2011.

For the nine months ended September 30, 2012, revenues increased approximately 31% to $78.3 million, compared to $59.7 million in the first nine months of 2011, supported by 60% commercial revenue growth internationally.  Currency fluctuations decreased revenue by seven percent compared to the same period in 2011. 

"We are pleased to have maintained strong international growth, particularly during the summer months of Europe, as 214 HeartWare® Ventricular Assist Systems were sold outside the U.S. in the third quarter of 2012, a 51% increase compared to 142 in the third quarter of last year," noted Doug Godshall, President and Chief Executive Officer.  "With the completion of enrollment in our Destination Therapy study in the United States, domestic revenue was primarily limited to the remaining slots in the Continued Access Protocol in the Bridge
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. HeartWare Schedules Third Quarter Conference Call And Webcast
2. HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
3. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
4. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
5. HeartWare Reports Second Quarter 2012 Results
6. HeartWare Completes Acquisition Of World Heart Corporation
7. HeartWare Schedules Second Quarter Conference Call And Webcast
8. HeartWare Names Peter F. McAree Chief Financial Officer
9. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
10. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
11. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
(Date:1/15/2014)... Jan. 15, 2014 As health officials across the Midwest ... Meijer pharmacies in Michigan will offer ... patients, enabling Meijer pharmacists to administer tests and, in some ... a physician participating in the study. The ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced ... Food and Drug Administration to manufacture and market,Ciclopirox ... The product has been determined to be ... Nail Lacquer, indicated for the,treatment of mild to ...
... Study Data Demonstrated Improved Progression-free Survival with Campath, ... ,Genzyme Corp. (Nasdaq: GENZ ) and Bayer ... that the U.S. Food and Drug Administration,(FDA) has ... (alemtuzumab) and granted regular approval for single-agent,Campath for ...
... Pa., Sept. 21 Cephalon, Inc. (Nasdaq:,CEPH) today ... Application (NDA) to,the U.S. Food and Drug Administration ... treatment of patients with chronic,lymphocytic leukemia (CLL). CLL ... with an estimated 15,000 new cases diagnosed every ...
... grains for breakfast, such as whole-grain barley or rye, ... breakfast, lunch, and dinner. It was previously not known ... This is due to a combination of low GI ... occur in certain grain products. The findings are presented ...
... study by researchers at the University of Southern California suggests ... Researchers found that a storyline on the primetime NBC network ... eating habits had a positive impact on the attitudes and ... in the Sept. 14 Journal of Health Communication and now ...
... Insights might produce treatments to kill off cancer cells, ... New information about a process called unplanned cell death, ... disease, cancer, stroke and other life-threatening conditions, scientists say. ... natural, healthy programmed cell death. Necrosis is an unplanned ...
Cached Medicine News:Health News:Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 3Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 4Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 5Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 6Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4Health News:Right breakfast bread keeps blood sugar in check all day 2Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Clues to Cell Death Could Fight Disease 2
... (IGF-1) is a polypeptide of 70 amino acids ... of related insulin-like growth factors present in the ... with proinsulin and has a number of biological ... hormone (GH) dependent to a high degree, but ...
...
...
...
Medicine Products: